These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16568247)

  • 1. Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease.
    Sawkar AR; D'Haeze W; Kelly JW
    Cell Mol Life Sci; 2006 May; 63(10):1179-92. PubMed ID: 16568247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substrate reduction therapy of glycosphingolipid storage disorders.
    Aerts JM; Hollak CE; Boot RG; Groener JE; Maas M
    J Inherit Metab Dis; 2006; 29(2-3):449-56. PubMed ID: 16763917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.
    Ivanova MM; Dao J; Kasaci N; Adewale B; Nazari S; Noll L; Fikry J; Sanati AH; Goker-Alpan O
    PLoS One; 2021; 16(10):e0247211. PubMed ID: 34695170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
    FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants.
    Sawkar AR; Schmitz M; Zimmer KP; Reczek D; Edmunds T; Balch WE; Kelly JW
    ACS Chem Biol; 2006 May; 1(4):235-51. PubMed ID: 17163678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucosylceramide mimics: highly potent GCase inhibitors and selective pharmacological chaperones for mutations associated with types 1 and 2 Gaucher disease.
    Schönemann W; Gallienne E; Ikeda-Obatake K; Asano N; Nakagawa S; Kato A; Adachi I; Górecki M; Frelek J; Martin OR
    ChemMedChem; 2013 Nov; 8(11):1805-17. PubMed ID: 24115322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease.
    Sawkar AR; Cheng WC; Beutler E; Wong CH; Balch WE; Kelly JW
    Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15428-33. PubMed ID: 12434014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
    Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E
    J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.
    Jung O; Patnaik S; Marugan J; Sidransky E; Westbroek W
    Expert Rev Proteomics; 2016 May; 13(5):471-9. PubMed ID: 27098312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
    Trapero A; Llebaria A
    Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fate of glucosylceramide (glucocerebroside) in genetically impaired (lysosomal beta-glucosidase deficient) Gaucher disease diploid human fibroblasts.
    Saito M; Rosenberg A
    J Biol Chem; 1985 Feb; 260(4):2295-300. PubMed ID: 3919000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
    Sánchez-Fernández EM; García Fernández JM; Mellet CO
    Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.
    Marshall J; McEachern KA; Chuang WL; Hutto E; Siegel CS; Shayman JA; Grabowski GA; Scheule RK; Copeland DP; Cheng SH
    J Inherit Metab Dis; 2010 Jun; 33(3):281-9. PubMed ID: 20336375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease.
    Aerts JMFG; Kuo CL; Lelieveld LT; Boer DEC; van der Lienden MJC; Overkleeft HS; Artola M
    Curr Opin Chem Biol; 2019 Dec; 53():204-215. PubMed ID: 31783225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles.
    Sawkar AR; Adamski-Werner SL; Cheng WC; Wong CH; Beutler E; Zimmer KP; Kelly JW
    Chem Biol; 2005 Nov; 12(11):1235-44. PubMed ID: 16298303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substrate reduction therapy for lysosomal storage diseases.
    Cox TM
    Acta Paediatr Suppl; 2005 Mar; 94(447):69-75; discussion 57. PubMed ID: 15895716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosphingolipid disorders of the brain.
    Boomkamp SD; Butters TD
    Subcell Biochem; 2008; 49():441-67. PubMed ID: 18751922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycosphingolipid analysis in a naturally occurring ovine model of acute neuronopathic Gaucher disease.
    Karageorgos L; Hein L; Rozaklis T; Adams M; Duplock S; Snel M; Hemsley K; Kuchel T; Smith N; Hopwood JJ
    Neurobiol Dis; 2016 Jul; 91():143-54. PubMed ID: 26976737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.